肺健康检查试点:爱尔兰的旗舰肺癌筛查试验。

IF 3.4 3区 医学 Q1 RESPIRATORY SYSTEM
David O Reilly, Sandra Roche, Claire Noonan, Jack O'Shea, Sinead Toomey, Bryan T Hennessy, Gerard J Fitzmaurice, Keith Egan, Jasmine Dunne, Catriona M Dowling, Ian Counihan, Emmet O'Brien, Imran Sulaiman, Ross Morgan, Benjamin Jacob, Anne-Marie Baird, Seamus Cotter, Donal Bailey, Gavin Maguire, Kathleen Bennett, Jan Sorensen, Nuala A Healy, James Ryan, Patrick Redmond, Daniel J Ryan, Jarushka Naidoo
{"title":"肺健康检查试点:爱尔兰的旗舰肺癌筛查试验。","authors":"David O Reilly, Sandra Roche, Claire Noonan, Jack O'Shea, Sinead Toomey, Bryan T Hennessy, Gerard J Fitzmaurice, Keith Egan, Jasmine Dunne, Catriona M Dowling, Ian Counihan, Emmet O'Brien, Imran Sulaiman, Ross Morgan, Benjamin Jacob, Anne-Marie Baird, Seamus Cotter, Donal Bailey, Gavin Maguire, Kathleen Bennett, Jan Sorensen, Nuala A Healy, James Ryan, Patrick Redmond, Daniel J Ryan, Jarushka Naidoo","doi":"10.1136/bmjresp-2024-003035","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Low-dose chest CT (LDCT) has demonstrated the ability to detect early-stage lung cancer (LC) and improve disease-specific mortality in high-risk individuals. Use of LC risk scores such as the Prostate, Lung, Colorectal, Ovarian Model Score (PLCO<sub>M2012</sub>) improves the sensitivity, specificity and positive predictive value for LC screening. Screening programmes have identified that primary care participation, patient engagement and improved accessibility may enhance the success of LC screening. Currently, there is no LC screening programme in Ireland. This first pilot study of LC screening will investigate (1) the feasibility, including uptake, of LC screening in a community setting, based on primary care-based participant invitation with mobile CT scanning and (2) novel blood/breath biomarkers in high-risk individuals who participate in the LC screening trial, to identify biologic parameters that may supplement existing risk scores, to maximise LC early detection.</p><p><strong>Methods and analysis: </strong>In a pilot feasibility clinical trial, approximately 30 000 adults aged between 55 and 74 from participating general practitioner (GP) practices will be invited to a 'lung health check (LHC)' prescreening, involving a telephone assessment of eligibility and risk status, based on the PLCO<sub>M2012</sub>/Liverpool Score V.2. High-risk individuals will be invited to the LHC, which will take place in a mobile unit strategically located in the community and include a respiratory disease assessment, baseline spirometry, smoking cessation advice, an LDCT and in a selected cohort, blood/breath/sputum biospecimen collection. Two rounds of screening will take place at an interval of 12 months.</p><p><strong>Ethics, dissemination and registration details: </strong>In this pilot feasibility trial, the uptake of LC screening using a community-based strategy among high-risk participants will be investigated. The study has been approved by Beaumont Hospital Research Ethics Committee and is registered with clinicaltrials.gov (NCT07099027). Novel features of our design include directly calling participants and our translational arm of the study, which will focus on blood/breath/sputum biomarkers associated with LC.</p>","PeriodicalId":9048,"journal":{"name":"BMJ Open Respiratory Research","volume":"12 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Lung Health Check pilot: Ireland's flagship lung cancer screening trial.\",\"authors\":\"David O Reilly, Sandra Roche, Claire Noonan, Jack O'Shea, Sinead Toomey, Bryan T Hennessy, Gerard J Fitzmaurice, Keith Egan, Jasmine Dunne, Catriona M Dowling, Ian Counihan, Emmet O'Brien, Imran Sulaiman, Ross Morgan, Benjamin Jacob, Anne-Marie Baird, Seamus Cotter, Donal Bailey, Gavin Maguire, Kathleen Bennett, Jan Sorensen, Nuala A Healy, James Ryan, Patrick Redmond, Daniel J Ryan, Jarushka Naidoo\",\"doi\":\"10.1136/bmjresp-2024-003035\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Low-dose chest CT (LDCT) has demonstrated the ability to detect early-stage lung cancer (LC) and improve disease-specific mortality in high-risk individuals. Use of LC risk scores such as the Prostate, Lung, Colorectal, Ovarian Model Score (PLCO<sub>M2012</sub>) improves the sensitivity, specificity and positive predictive value for LC screening. Screening programmes have identified that primary care participation, patient engagement and improved accessibility may enhance the success of LC screening. Currently, there is no LC screening programme in Ireland. This first pilot study of LC screening will investigate (1) the feasibility, including uptake, of LC screening in a community setting, based on primary care-based participant invitation with mobile CT scanning and (2) novel blood/breath biomarkers in high-risk individuals who participate in the LC screening trial, to identify biologic parameters that may supplement existing risk scores, to maximise LC early detection.</p><p><strong>Methods and analysis: </strong>In a pilot feasibility clinical trial, approximately 30 000 adults aged between 55 and 74 from participating general practitioner (GP) practices will be invited to a 'lung health check (LHC)' prescreening, involving a telephone assessment of eligibility and risk status, based on the PLCO<sub>M2012</sub>/Liverpool Score V.2. High-risk individuals will be invited to the LHC, which will take place in a mobile unit strategically located in the community and include a respiratory disease assessment, baseline spirometry, smoking cessation advice, an LDCT and in a selected cohort, blood/breath/sputum biospecimen collection. Two rounds of screening will take place at an interval of 12 months.</p><p><strong>Ethics, dissemination and registration details: </strong>In this pilot feasibility trial, the uptake of LC screening using a community-based strategy among high-risk participants will be investigated. The study has been approved by Beaumont Hospital Research Ethics Committee and is registered with clinicaltrials.gov (NCT07099027). Novel features of our design include directly calling participants and our translational arm of the study, which will focus on blood/breath/sputum biomarkers associated with LC.</p>\",\"PeriodicalId\":9048,\"journal\":{\"name\":\"BMJ Open Respiratory Research\",\"volume\":\"12 1\",\"pages\":\"\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMJ Open Respiratory Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1136/bmjresp-2024-003035\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Open Respiratory Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/bmjresp-2024-003035","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

摘要

低剂量胸部CT (LDCT)已被证明能够检测早期肺癌(LC)并改善高危人群的疾病特异性死亡率。使用前列腺、肺、结直肠、卵巢模型评分(PLCOM2012)等LC风险评分可提高LC筛查的敏感性、特异性和阳性预测值。筛查项目已经确定,初级保健的参与、患者的参与和可及性的提高可能会提高LC筛查的成功率。目前,爱尔兰没有LC筛查计划。LC筛查的第一个试点研究将调查(1)在社区环境中进行LC筛查的可行性,包括采用移动CT扫描的基于初级保健的参与者邀请;(2)参与LC筛查试验的高风险个体的新型血液/呼吸生物标志物,以确定可能补充现有风险评分的生物学参数,以最大限度地提高LC的早期发现。方法和分析:在一项试点可行性临床试验中,约30,000名年龄在55至74岁之间的全科医生(GP)将被邀请参加“肺部健康检查(LHC)”预筛查,包括基于PLCOM2012/Liverpool Score V.2的资格和风险状况的电话评估。高风险个体将被邀请参加LHC, LHC将在位于社区战略位置的移动单元中进行,包括呼吸疾病评估、基线肺活量测定、戒烟建议、LDCT和选定队列的血液/呼吸/痰生物标本收集。每隔12个月进行两轮筛选。伦理、传播和注册细节:在这项试点可行性试验中,将调查在高风险参与者中使用社区策略进行LC筛查的情况。该研究已获得Beaumont医院研究伦理委员会的批准,并在clinicaltrials.gov注册(NCT07099027)。我们设计的新颖特征包括直接呼叫参与者和我们研究的翻译部分,这将重点关注与LC相关的血液/呼吸/痰生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Lung Health Check pilot: Ireland's flagship lung cancer screening trial.

Introduction: Low-dose chest CT (LDCT) has demonstrated the ability to detect early-stage lung cancer (LC) and improve disease-specific mortality in high-risk individuals. Use of LC risk scores such as the Prostate, Lung, Colorectal, Ovarian Model Score (PLCOM2012) improves the sensitivity, specificity and positive predictive value for LC screening. Screening programmes have identified that primary care participation, patient engagement and improved accessibility may enhance the success of LC screening. Currently, there is no LC screening programme in Ireland. This first pilot study of LC screening will investigate (1) the feasibility, including uptake, of LC screening in a community setting, based on primary care-based participant invitation with mobile CT scanning and (2) novel blood/breath biomarkers in high-risk individuals who participate in the LC screening trial, to identify biologic parameters that may supplement existing risk scores, to maximise LC early detection.

Methods and analysis: In a pilot feasibility clinical trial, approximately 30 000 adults aged between 55 and 74 from participating general practitioner (GP) practices will be invited to a 'lung health check (LHC)' prescreening, involving a telephone assessment of eligibility and risk status, based on the PLCOM2012/Liverpool Score V.2. High-risk individuals will be invited to the LHC, which will take place in a mobile unit strategically located in the community and include a respiratory disease assessment, baseline spirometry, smoking cessation advice, an LDCT and in a selected cohort, blood/breath/sputum biospecimen collection. Two rounds of screening will take place at an interval of 12 months.

Ethics, dissemination and registration details: In this pilot feasibility trial, the uptake of LC screening using a community-based strategy among high-risk participants will be investigated. The study has been approved by Beaumont Hospital Research Ethics Committee and is registered with clinicaltrials.gov (NCT07099027). Novel features of our design include directly calling participants and our translational arm of the study, which will focus on blood/breath/sputum biomarkers associated with LC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
BMJ Open Respiratory Research
BMJ Open Respiratory Research RESPIRATORY SYSTEM-
CiteScore
6.60
自引率
2.40%
发文量
95
审稿时长
12 weeks
期刊介绍: BMJ Open Respiratory Research is a peer-reviewed, open access journal publishing respiratory and critical care medicine. It is the sister journal to Thorax and co-owned by the British Thoracic Society and BMJ. The journal focuses on robustness of methodology and scientific rigour with less emphasis on novelty or perceived impact. BMJ Open Respiratory Research operates a rapid review process, with continuous publication online, ensuring timely, up-to-date research is available worldwide. The journal publishes review articles and all research study types: Basic science including laboratory based experiments and animal models, Pilot studies or proof of concept, Observational studies, Study protocols, Registries, Clinical trials from phase I to multicentre randomised clinical trials, Systematic reviews and meta-analyses.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信